ESC 365 - Cardiovascular effects of GLP-1 receptor agonists.

Open Access

Cardiovascular effects of GLP-1 receptor agonists.

Session: Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

Topic: Diabetes, dysglycaemia and metabolic syndrome

Speaker: Doctor J. Plutzky (Boston, US)

Sponsored by Novo Nordisk

Event: ESC Congress 2017

Congress Presentation

Add to my library

About the speaker

Doctor Jorge Plutzky

Brigham and Women's Hospital, Boston (United States of America)

5 presentations

0 follower

4 more presentations in this session

Introduction: cardiovascular disease in type 2 diabetes – Where do we come from.

Speaker: Professor L. Ryden (Stockholm, SE)

Results from the LEADER cardiovascular outcomes trial.

Speaker: Professor N. Poulter (London, GB)

Perspectives on results from recent CVOTs in type 2 diabetes.

Speaker: Professor L. Ryden (Stockholm, SE)

Panel discussion - Improving CV outcomes in type 2 diabetes: A novel role for GLP-1 receptor agonists?

Speaker: Professor L. Ryden (Stockholm, SE) Doctor J. Plutzky (Boston, US) Professor N. Poulter (London, GB)

Access the full session

Improving cardiovascular outcomes in type 2 diabetes: a novel role for GLP-1 receptor agonists?

Speakers: Doctor J. Plutzky, Professor L. Ryden, Professor N. Poulter, Professor L. Ryden, Professor L. Ryden...

About the event

ESC Congress 2017

26 August - 30 August 2017

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources